Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus

Background Human growth factors are potential therapeutic agents for various inflammatory disorders affecting the gastrointestinal tract. However, they are unstable when administered orally and systemic administration requires high doses increasing the risk of unwanted side effects. Live microorganism-based delivery systems can overcome these problems although they suffer from the inability to control heterologous protein production and there are concerns regarding biosafety and environmental contamination. Methods To overcome these limitations we have developed a new live bacteria drug-delivery system using the human commensal gut bacterium Bacteroides ovatus engineered to secrete human growth factors in response to dietary xylan. The anaerobic nature of B ovatus provides an inherent biosafety feature. B ovatus strains expressing human keratinocyte growth factor-2, which plays a central role in intestinal epithelial homeostasis and repair (BO-KGF), were generated by homologous recombination and evaluated using the dextran sodium sulfate (DSS)-induced model of intestinal epithelial injury and colitis. Results In response to xylan BO-KGF produced biologically active KGF both in vitro and in vivo. In DSS treated mice administration of xylan and BO-KGF had a significant therapeutic effect in reducing weight loss, improving stool consistency, reducing rectal bleeding, accelerating healing of damaged epithelium, reducing inflammation and neutrophil infiltration, reducing expression of pro-inflammatory cytokines, and accelerating production of goblet cells. BO-KGF and xylan treatment also had a marked prophylactic effect limiting the development of inflammation and disruption of the epithelial barrier. Conclusion This novel, diet-regulated, live bacterial drug delivery system may be applicable to treating various bowel disorders.

[1]  A. Dignass.  Mechanisms and modulation of intestinal epithelial repair. , 2001, Inflammatory bowel diseases.

[2]  R. B. Hespell,et al.  The genes for three xylan-degrading activities from Bacteroides ovatus are clustered in a 3.8-kilobase region , 1990, Journal of bacteriology.

[3]  S. Erdman,et al.  Supply and Release of Storage Neutrophils , 1982 .

[4]  Daniel K. Podolsky,et al.  Trefoil factors: initiators of mucosal healing , 2003, Nature Reviews Molecular Cell Biology.

[5]  L. Frati,et al.  Differential response to keratinocyte growth factor receptor and epidermal growth factor receptor ligands of proliferating and differentiating intestinal epithelial cells , 2004, Journal of cellular physiology.

[6]  G. Rogler,et al.  Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. , 2001, Gastroenterology.

[7]  W. Fiers,et al.  Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. , 2000, Science.

[8]  B. Sands,et al.  Repifermin (keratinocyte growth factor‐2) for the treatment of active ulcerative colitis: a randomized, double‐blind, placebo‐controlled, dose‐escalation trial , 2003, Alimentary pharmacology & therapeutics.

[9]  S. Carding,et al.  Uptake and presentation of antigen to T cells by primary colonic epithelial cells in normal and diseased states. , 2000, Gastroenterology.

[10]  T. Hudcovic,et al.  Monocolonization with Bacteroides ovatus protects immunodeficient SCID mice from mortality in chronic intestinal inflammation caused by long-lasting dextran sodium sulfate treatment. , 2009, Physiological research.

[11]  Erik Remaut,et al.  A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  R. Sartor,et al.  Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[13]  K. T. Holland,et al.  Identification and use of the putative Bacteroides ovatus xylanase promoter for the inducible production of recombinant human proteins. , 2008, Microbiology.

[14]  J. Parajó,et al.  Advances in the manufacture, purification and applications of xylo-oligosaccharides as food additives and nutraceuticals , 2006 .

[15]  D. Lacey,et al.  Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. , 1998, International journal of radiation oncology, biology, physics.

[16]  S. Erdman,et al.  Supply and release of storage neutrophils. A developmental study. , 1982, Biology of the neonate.

[17]  W. Sandborn,et al.  Inflammatory bowel disease: clinical aspects and established and evolving therapies , 2007, The Lancet.

[18]  P. Felsburg,et al.  Toll-like receptor-mediated responses of primary intestinal epithelial cells during the development of colitis. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[19]  W. Dörr,et al.  Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental studies in mice. , 2005, International journal of radiation oncology, biology, physics.

[20]  Jean Paul Remon,et al.  Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10 , 2003, Nature Biotechnology.

[21]  M. Sakamoto,et al.  Bacteroides ovatus as the Predominant Commensal Intestinal Microbe Causing a Systemic Antibody Response in Inflammatory Bowel Disease , 2002, Clinical and Vaccine Immunology.

[22]  D. Lacey,et al.  Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats. , 1996, Gastroenterology.

[23]  H. Ogata,et al.  Animal models of inflammatory bowel disease , 2002, Journal of Gastroenterology.

[24]  A. Salyers,et al.  Utilization of Xylan by Two Species of Human Colonic Bacteroides , 1981, Applied and environmental microbiology.

[25]  T. Coleman,et al.  Efficacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis. , 1999, The Journal of pharmacology and experimental therapeutics.

[26]  C. Elson,et al.  Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. , 1994, Gastroenterology.

[27]  E. Loftus.  Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. , 2004, Gastroenterology.

[28]  R. Flisiak,et al.  Effect of ulcerative colitis activity on plasma concentration of transforming growth factor beta1. , 2001, Cytokine.

[29]  D. Lacey,et al.  The effects of keratinocyte growth factor in preclinical models of mucositis , 2002, Cell proliferation.

[30]  S. Werner,et al.  Keratinocyte growth factor: a unique player in epithelial repair processes. , 1998, Cytokine & growth factor reviews.

[31]  R. Turner,et al.  Bacterial Populations Associated with Different Regions of the Human Colon Wall , 1983, Applied and environmental microbiology.

[32]  M. Feldhaus,et al.  Location and characterization of genes involved in binding of starch to the surface of Bacteroides thetaiotaomicron , 1992, Journal of bacteriology.